FDA Grants AP Status for Levonorgestrel and Ethinyl Estradiol ANDA200492
The FDA has granted an Abbreviated Approval (AP) status for ANDA200492, a combination of Levonorgestrel and Ethinyl Estradiol.
Asset / Drug
Drug and asset intelligence for Xiromed with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.